Consequently, our results prove that female advanced colorectal adenocarcinoma patients with lower risk scores are more likely to benefit from immunotherapy of anti-CTLA-4, anti-PDL1, and anti-PDL2 than those with higher risk scores. The gene discussed is CTLA4; the disease is colorectal adenocarcinoma.